Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2026 | 850 | 1.290 |
Why?
|
| Chemical and Drug Induced Liver Injury | 4 | 2026 | 146 | 1.260 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2025 | 575 | 1.120 |
Why?
|
| Neuroblastoma | 4 | 2021 | 544 | 0.730 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2021 | 57 | 0.680 |
Why?
|
| Aurora Kinase A | 1 | 2021 | 36 | 0.670 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 614 | 0.660 |
Why?
|
| Gene Amplification | 1 | 2021 | 222 | 0.650 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 726 | 0.600 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 265 | 0.600 |
Why?
|
| Proteins | 2 | 2021 | 1015 | 0.580 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 56 | 0.500 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 60 | 0.490 |
Why?
|
| Wilms Tumor | 1 | 2016 | 117 | 0.460 |
Why?
|
| Rhabdoid Tumor | 2 | 2026 | 49 | 0.430 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 25 | 0.420 |
Why?
|
| Antineoplastic Agents | 5 | 2026 | 1796 | 0.410 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2014 | 84 | 0.390 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2024 | 80 | 0.380 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 420 | 0.370 |
Why?
|
| alpha-Thalassemia | 1 | 2009 | 11 | 0.300 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2009 | 12 | 0.300 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 2009 | 37 | 0.290 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 622 | 0.270 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2024 | 165 | 0.250 |
Why?
|
| Child | 14 | 2026 | 26160 | 0.240 |
Why?
|
| Induction Chemotherapy | 1 | 2025 | 53 | 0.230 |
Why?
|
| Superoxide Dismutase | 1 | 2026 | 176 | 0.230 |
Why?
|
| Fetal Diseases | 1 | 2009 | 445 | 0.220 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 1350 | 0.210 |
Why?
|
| Apoptosis | 3 | 2021 | 1843 | 0.200 |
Why?
|
| Small Molecule Libraries | 2 | 2022 | 132 | 0.190 |
Why?
|
| Metabolome | 1 | 2025 | 325 | 0.190 |
Why?
|
| Methyltransferases | 2 | 2015 | 78 | 0.190 |
Why?
|
| Cell Lineage | 1 | 2024 | 346 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2026 | 379 | 0.190 |
Why?
|
| Nuclear Proteins | 3 | 2026 | 1229 | 0.190 |
Why?
|
| Humans | 26 | 2026 | 130372 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 999 | 0.190 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 244 | 0.190 |
Why?
|
| Lipids | 1 | 2026 | 562 | 0.180 |
Why?
|
| Electronics | 1 | 2022 | 45 | 0.180 |
Why?
|
| Selenium | 1 | 2022 | 14 | 0.180 |
Why?
|
| Mutation | 2 | 2024 | 6131 | 0.180 |
Why?
|
| Contraceptive Agents, Male | 1 | 2022 | 37 | 0.180 |
Why?
|
| Metabolomics | 1 | 2025 | 504 | 0.170 |
Why?
|
| Pyrazines | 1 | 2021 | 79 | 0.170 |
Why?
|
| Cell Survival | 2 | 2021 | 837 | 0.170 |
Why?
|
| Aniline Compounds | 2 | 2021 | 20 | 0.170 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 3720 | 0.170 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 53 | 0.170 |
Why?
|
| Drug Discovery | 1 | 2022 | 178 | 0.160 |
Why?
|
| Supratentorial Neoplasms | 1 | 2021 | 41 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 2026 | 0.160 |
Why?
|
| Language Development Disorders | 1 | 2022 | 177 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 1262 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 298 | 0.160 |
Why?
|
| Cell Proliferation | 4 | 2021 | 2478 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1312 | 0.160 |
Why?
|
| Child, Preschool | 8 | 2026 | 14984 | 0.160 |
Why?
|
| Mice | 6 | 2022 | 18213 | 0.150 |
Why?
|
| Ependymoma | 1 | 2021 | 154 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 1608 | 0.140 |
Why?
|
| Gene Editing | 1 | 2021 | 227 | 0.140 |
Why?
|
| Transcription Factors | 3 | 2026 | 2457 | 0.140 |
Why?
|
| Animals | 9 | 2026 | 33924 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2017 | 15 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2026 | 2847 | 0.130 |
Why?
|
| Spiro Compounds | 1 | 2016 | 11 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 79 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2017 | 92 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 2016 | 48 | 0.120 |
Why?
|
| Autism Spectrum Disorder | 1 | 2022 | 445 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2016 | 33 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2016 | 53 | 0.120 |
Why?
|
| Nitriles | 1 | 2017 | 161 | 0.120 |
Why?
|
| Quinolines | 1 | 2017 | 117 | 0.120 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2022 | 622 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 767 | 0.110 |
Why?
|
| Indoles | 1 | 2016 | 199 | 0.110 |
Why?
|
| SMARCB1 Protein | 2 | 2026 | 42 | 0.110 |
Why?
|
| Intellectual Disability | 1 | 2022 | 1080 | 0.110 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2026 | 70 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2021 | 5069 | 0.110 |
Why?
|
| Fibrosarcoma | 1 | 2014 | 22 | 0.110 |
Why?
|
| Infant | 6 | 2026 | 13269 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 116 | 0.100 |
Why?
|
| Neutropenia | 1 | 2015 | 203 | 0.100 |
Why?
|
| Neoplasms | 2 | 2021 | 2944 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2356 | 0.100 |
Why?
|
| DNA Helicases | 2 | 2026 | 234 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1232 | 0.100 |
Why?
|
| Fever | 1 | 2015 | 306 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1976 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 568 | 0.090 |
Why?
|
| Female | 8 | 2026 | 70274 | 0.090 |
Why?
|
| Structure-Activity Relationship | 3 | 2022 | 552 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2025 | 50 | 0.090 |
Why?
|
| Oncogenes | 2 | 2022 | 163 | 0.090 |
Why?
|
| Adolescent | 6 | 2026 | 20747 | 0.080 |
Why?
|
| Prognosis | 2 | 2026 | 4893 | 0.080 |
Why?
|
| Histones | 1 | 2015 | 546 | 0.080 |
Why?
|
| Medulloblastoma | 1 | 2014 | 390 | 0.080 |
Why?
|
| Phenotype | 2 | 2022 | 4475 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2015 | 698 | 0.070 |
Why?
|
| Chimerism | 1 | 2009 | 28 | 0.070 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 141 | 0.070 |
Why?
|
| Graft Survival | 1 | 2009 | 461 | 0.060 |
Why?
|
| Idarubicin | 1 | 2025 | 7 | 0.060 |
Why?
|
| Young Adult | 3 | 2025 | 9989 | 0.060 |
Why?
|
| Male | 6 | 2026 | 64517 | 0.060 |
Why?
|
| Cytarabine | 1 | 2025 | 99 | 0.060 |
Why?
|
| Vidarabine | 1 | 2025 | 91 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2009 | 502 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2025 | 91 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2017 | 701 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2016 | 289 | 0.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2024 | 69 | 0.050 |
Why?
|
| Prenatal Diagnosis | 1 | 2009 | 623 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 41 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2009 | 773 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2545 | 0.050 |
Why?
|
| Morpholines | 1 | 2023 | 67 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2025 | 294 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2023 | 75 | 0.050 |
Why?
|
| Benzamides | 1 | 2023 | 125 | 0.050 |
Why?
|
| Phenylurea Compounds | 2 | 2015 | 56 | 0.050 |
Why?
|
| Adenosine | 2 | 2015 | 118 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2002 | 37 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 348 | 0.050 |
Why?
|
| Pyridones | 1 | 2023 | 147 | 0.050 |
Why?
|
| Teratoma | 1 | 2023 | 121 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 45 | 0.040 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2021 | 31 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 85 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2002 | 125 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 810 | 0.040 |
Why?
|
| Serotonin | 1 | 2002 | 211 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 132 | 0.040 |
Why?
|
| Protein Domains | 1 | 2022 | 253 | 0.040 |
Why?
|
| Logistic Models | 1 | 2026 | 1799 | 0.040 |
Why?
|
| Remission Induction | 1 | 2022 | 300 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 504 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 599 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8493 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2024 | 546 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2022 | 274 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 326 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2017 | 4675 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 721 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 345 | 0.040 |
Why?
|
| Aorta | 1 | 2002 | 520 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2026 | 3387 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4664 | 0.030 |
Why?
|
| Texas | 1 | 2026 | 3626 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 85 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1419 | 0.030 |
Why?
|
| Indolizines | 1 | 2016 | 10 | 0.030 |
Why?
|
| Cyclic N-Oxides | 1 | 2016 | 19 | 0.030 |
Why?
|
| Pyridinium Compounds | 1 | 2016 | 27 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 7381 | 0.030 |
Why?
|
| Biomarkers | 1 | 2026 | 3393 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 6186 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2012 | 1019 | 0.030 |
Why?
|
| S-Adenosylmethionine | 1 | 2015 | 27 | 0.030 |
Why?
|
| Methylation | 1 | 2015 | 197 | 0.030 |
Why?
|
| Ligands | 1 | 2015 | 487 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1617 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 1577 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 694 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2012 | 54 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2012 | 145 | 0.020 |
Why?
|
| Catalysis | 1 | 2012 | 137 | 0.020 |
Why?
|
| Risk Factors | 1 | 2026 | 10937 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1058 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2012 | 286 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2012 | 159 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2015 | 895 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 1087 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 812 | 0.020 |
Why?
|
| United States | 1 | 2023 | 11819 | 0.020 |
Why?
|
| Adult | 1 | 2025 | 31117 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 6421 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17606 | 0.010 |
Why?
|
| Denervation | 1 | 2002 | 23 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 938 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 1113 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2002 | 1018 | 0.010 |
Why?
|
| Swine | 1 | 2002 | 1184 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 3400 | 0.010 |
Why?
|